Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Apr;25(2):313-326.
doi: 10.1007/s00737-021-01185-6. Epub 2022 Jan 1.

Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials

Robyn R Jones  1 , Marlene P Freeman  2 , Susan G Kornstein  3 , Kimberly Cooper  4 , Ella J Daly  5 , Carla M Canuso  6 , Susan Nicholson  7
Affiliations
Randomized Controlled Trial

Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials

Robyn R Jones et al. Arch Womens Ment Health. 2022 Apr.

Abstract

The objective of this analysis was to determine if there are sex differences with esketamine for treatment-resistant depression (TRD). Post hoc analyses of three randomized, controlled studies of esketamine in patients with TRD (TRANSFORM-1, TRANSFORM-2 [18-64 years], TRANSFORM-3 [≥ 65 years]) were performed. In each 4-week study, adults with TRD were randomized to esketamine or placebo nasal spray, each with a newly initiated oral antidepressant. Change from baseline to day 28 in Montgomery-Åsberg Depression Rating Scale (MADRS) total score was assessed by sex in pooled data from TRANSFORM-1/TRANSFORM-2 and separately in data from TRANSFORM-3 using a mixed-effects model for repeated measures. Use of hormonal therapy was assessed in all women, and menopausal status was assessed in women in TRANSFORM-1/TRANSFORM-2. Altogether, 702 adults (464 women) received ≥ 1 dose of intranasal study drug and antidepressant. Mean MADRS total score (SD) decreased from baseline to day 28, more so among patients treated with esketamine/antidepressant vs. antidepressant/placebo in both women and men: TRANSFORM-1/TRANSFORM-2 women-esketamine/antidepressant -20.3 (13.19) vs. antidepressant/placebo -15.8 (14.67), men-esketamine/antidepressant -18.3 (14.08) vs. antidepressant/placebo -16.0 (14.30); TRANSFORM-3 women-esketamine/antidepressant -9.9 (13.34) vs. antidepressant/placebo -6.9 (9.65), men-esketamine/antidepressant -10.3 (11.96) vs. antidepressant/placebo -5.5 (7.64). There was no significant sex effect or treatment-by-sex interaction (p > 0.35). The most common adverse events in esketamine-treated patients were nausea, dissociation, dizziness, and vertigo, each reported at a rate higher in women than men. The analyses support antidepressant efficacy and overall safety of esketamine nasal spray are similar between women and men with TRD. The TRANSFORM studies are registered at clinicaltrials.gov (identifiers: NCT02417064 (first posted 15 April 2015; last updated 4 May 2020), NCT02418585 (first posted 16 April 2015; last updated 2 June 2020), and NCT02422186 (first posted 21 April 2015; last updated 29 September 2021)).

Keywords: Esketamine; Sex; Treatment-resistant depression; s-Ketamine.

PubMed Disclaimer

Conflict of interest statement

Robyn R. Jones, Kimberly Cooper, Ella Daly, Carla M. Canuso, and Susan Nicholson are employees of Janssen Research & Development, LLC and hold company equity. Dr. Marlene Freeman reports Investigator-Initiated Trials/Research: JayMac, Sage; Advisory Boards: Eliem, Sage; Independent Data Safety and Monitoring Committee: Janssen (Johnson & Johnson), Novartis; Steering Committee for Educational Activities: Medscape; and Educational Activities: WebMD. Dr. Freeman is an employee of Massachusetts General Hospital, and works with the MGH National Pregnancy Registry [Current Registry Sponsors: Teva (2018-present), Alkermes, Inc. (2016-present); Otsuka America Pharmaceutical, Inc. (2008-present); Forest/Actavis (2016-present); Sunovion Pharmaceuticals, Inc. (2011-present)]. As an employee of MGH, Dr. Freeman works with the MGH CTNI, which has had research funding from multiple pharmaceutical companies and NIMH. Dr. Susan Kornstein reports Research Support: Pfizer, Allergan, Marinus, Takeda, Palatin, National Science Foundation; Consulting/Advisory Boards: Pfizer, Marinus, Sage, Acadia, Sunovion, Shire, Allergan, Palatin, AbbVie; and Royalties: Guilford Press.

Figures

Fig. 1
Fig. 1
Response and remission rates by sex and treatment group in the TRANSFORM trials. CI = confidence interval. Notes: Response defined as ≥ 50% decrease from baseline Montgomery-Asberg Depression Rating Scale (MADRS) total score. Remission defined as MADRS total score ≤ 12. Odds ratio = odds of achieving response on esketamine + antidepressant divided by the odds of achieving response on antidepressant + placebo
Fig. 2
Fig. 2
Response rates by menopausal status and treatment group in TRANSFORM trials. Notes: Response defined as ≥ 50% decrease from baseline Montgomery-Asberg Depression Rating Scale (MADRS) total score
Fig. 3
Fig. 3
Difference in least square means for SDS, PHQ-9, and GAD-7 total score by sex in pooled TRANSFORM-1/TRANSFORM-2 trials. CI = confidence interval; GAD-7 = Generalized Anxiety Disorder 7-item; LS = least squares; PHQ-9 = Patient Health Questionnaire 9-item; SDS = Sheehan Disability Scale. Notes: SDS total score ranges from 0 to 30; a higher score indicates greater impairment. PHQ-9 total score ranges from 0 to 27; a higher score indicates greater depression. GAD-7 total score ranges from 0 to 21; a higher score indicates more anxiety. Negative change in SDS total score, PHQ-9 total score, and GAD-7 total score indicates improvement for each, and a negative difference favors esketamine
See this image and copyright information in PMC

References

    1. American Psychiatric Association . Diagnostic and statistical manual of mental disorders, 5th edition: DSM-5. Arlington, TX: American Psychiatric Publishing; 2013.
    1. Anderson GD. Gender differences in pharmacological response. Int Rev Neurobiol. 2008;83:1–10. doi: 10.1016/S0074-7742(08)00001-9. - DOI - PubMed
    1. Berlanga C, Flores-Ramos M (2006) Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. J Affect Disord 95(1–3):119–123. 10.1016/j.jad.2006.04.029 - PubMed
    1. Bigos KL, Pollock BG, Stankevich BA, Bies RR. Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: an updated review. Gend Med. 2009;6(4):522–543. doi: 10.1016/j.genm.2009.12.004. - DOI - PubMed
    1. Cassano P, Soares CN, Cusin C, Mascarini A, Cohen LS, Fava M. Antidepressant response and well-being in pre-, peri- and postmenopausal women with major depressive disorder treated with fluoxetine. Psychother Psychosom. 2005;74(6):362–365. doi: 10.1159/000087783. - DOI - PubMed

Publication types

Associated data